Picket pharmaceuticals

What Picket pharmaceuticals does

Picket Pharmaceuticals, Inc., a privately held company headquartered in New York and founded in 2018, develops and brings to market complex generic pharmaceutical products that target medicines at risk for US drug shortages. The company operates on a shortage-forecasting thesis: a proprietary AI/ML data platform combines a generic-medicine "Moneyball" strategy with predictive analytics and anomaly detection over structured supply, active-ingredient, and macroeconomic data to identify undervalued essential medicines before shortages materialize. Once an asset is selected, Picket in-licenses or acquires it through its industry network and routes it to domestic manufacturing partners for production, targeting direct supply to hospitals and healthcare providers experiencing shortages. A stated five-year goal is to reduce US generic drug shortages by 10%.

The disclosed pipeline comprises five complex generics in development or filing across oncology (Irinotecan HCL for colorectal and small-cell lung cancer; Anastrozole for postmenopausal breast cancer), diabetes (Pioglitazon HCL), osteoporosis (Alendronate Sodium), and hypertension (Irbesartan). None of these assets are listed as approved or in commercialization on the company website. The team is small (1–10 employees) and includes a Founder/CEO with healthcare and statistical leadership experience, a Director of Data Science who serves as chief architect of the product-selection model, a Lead Counsel with two decades in generics, and former FDA regulatory and healthcare-investing advisors.

The commercial model is B2B enterprise field sales to hospitals, health systems, and payors, with revenue mechanics based on contract sales of generic products; pricing is negotiated and not publicly disclosed. The company has disclosed one early-stage funding round (January 2021) with E Squared Capital Management and Interplay, and currently operates only within the United States with no reported expansion outside its domestic market.

Name

Picket pharmaceuticals

Legal name

Picket Pharmaceuticals, Inc.

Website

https://picketpharmaceuticals.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Picket Pharmaceuticals is a privately held, New York–based pharmaceutical company that uses a proprietary AI/ML platform to identify and commercialize undervalued essential generic medicines at risk of US drug shortages, supplying hospitals, health systems, and payors through domestic manufacturing partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Oral Solid Dose (OSD) Generics (HLAIABAD), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Drug shortage prevention
• Essential medicines
• Complex generics
• Pharmaceutical manufacturing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Generic Pharmaceutical Product Sales: Picket Pharmaceuticals generates revenue by manufacturing and commercializing generic essential medicines that are at risk for shortage. They identify undervalued essential medicines using their AI platform, then bring these products to market to fill unmet needs and stabilize markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Picket Pharmaceuticals develops, in-licenses, manufactures, and commercializes complex generic essential medicines that are at risk for supply shortages. The company uses a proprietary AI/ML data platform to forecast drug shortages and identify undervalued medicines, then manufactures and brings these products to market through partnerships with domestic manufacturers to supply hospitals and healthcare institutions across the United States.

Product overview

Picket Pharmaceuticals operates as a single-platform pharmaceutical company focused on preventing drug shortages through a proprietary AI/ML-powered data platform. The company identifies undervalued essential medicines at risk for shortage, then manufactures and commercializes these products using an established network of industry partners. The product portfolio includes five generic medications currently in development: Irinotecan HCL (oncology injection), Anastrozole (breast cancer oral treatment), Pioglitazon HCL (diabetes medication), Alendronate Sodium (osteoporosis treatment), and Irbesartan (hypertension treatment). The platform serves as the core differentiator, enabling rapid identification and execution on market opportunities before shortages occur.

Differentiator

Problem solved

Functional benefit

Products and services

• Irinotecan HCL Oncology injection used to treat cancer of the colon and rectum and some types of small cell lung cancer; complex generic currently in development and filing phase in Picket's pipeline.
• Anastrozole Oral solid generic oncology medication used to treat breast cancer in postmenopausal women by decreasing the amount of estrogen the body makes; currently in development phase in Picket's pipeline.
• Pioglitazon HCL Thiazolidinedione-type generic diabetes medication used along with diet and exercise to control high blood sugar in patients with type 2 diabetes by helping restore the body's proper response to insulin; currently in development phase in Picket's pipeline.
• Alendronate Sodium Generic medication used to prevent and treat osteoporosis in adults by slowing bone loss and reducing the risk of bones becoming thinner and breaking more easily; currently in development phase in Picket's pipeline.
• Irbesartan Angiotensin receptor blocker (ARB) generic used to treat hypertension and to help protect the kidneys from damage due to diabetes by relaxing blood vessels so blood flows more easily; currently in development phase in Picket's pipeline.

Quantifiable outcome

• 100% of hospitals experience drug shortages, most experiencing shortages of over 21 drugs in a 6-month period
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

One partnership is on record.

• Manufacturing PartnerscoreStrategic or Co-development PartnerPicket Pharmaceuticals provides manufacturing partners with acquired pharmaceutical products to enable faster, high-quality domestic manufacturing. These partnerships are essential to the company's model of reducing foreign supply exposure and filling unmet needs from drug shortages.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Sandoz: The global generic pharmaceuticals division of Novartis and one of the world's largest generic manufacturers, with a portfolio overlapping Picket's pipeline areas (oncology, hypertension, diabetes, osteoporosis). Operates broadly rather than in Picket's shortage-forecasting niche.
• Viatris: Global healthcare company formed via Mylan-Upjohn combination, with a substantial generics portfolio including hospital-channel injectables. Comparable product overlap with Picket, though Viatris operates at materially larger scale across many categories.
• Apotex: Large Canadian-headquartered generic pharmaceutical manufacturer with substantial US presence across oral solids and injectables. Competes in similar therapeutic categories (oncology, cardiovascular, diabetes) as Picket's pipeline.
• Endo International: Specialty pharmaceutical company with significant generics and sterile injectables businesses, including a hospital-focused portfolio. Overlaps with Picket's target customers and dosage forms, though Endo operates at much greater scale and breadth.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer, with a vast portfolio spanning many of the same therapeutic categories as Picket's pipeline (oncology, hypertension, diabetes). A broad incumbent rather than a shortage-focused specialist.

Regional players

• Zydus Pharmaceuticals: India-headquartered generic pharmaceutical company with significant US operations, including specialty injectables and oral solids. Overlaps with Picket's product categories (oncology, diabetes, hypertension) though at much larger scale and as a vertically integrated manufacturer.
• Aurobindo Pharma: India-based global generic manufacturer with extensive US operations across injectables, oral solids, and oncology generics. Overlaps with Picket's therapeutic categories and dosage forms, though operates as a vertically integrated global generics platform.

Direct peers

• Lannett Company: Small US generic pharmaceutical manufacturer with a portfolio of essential medicines across multiple therapeutic categories. Comparable scale and product breadth to Picket's pre-commercial pipeline.
• Hikma Pharmaceuticals: Specialty generic pharmaceutical company with a leading US hospital injectables franchise. Directly comparable to Picket in target customer (US hospitals), dosage forms (injectables + OSD), and shortage-response positioning.
• Amneal Pharmaceuticals: US-based generic pharmaceutical manufacturer with a strong complex-generics and injectables portfolio, targeting similar hospital and institutional channels. Comparable in product mix (sterile injectables, oral solids) and customer base to Picket's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Picket pharmaceuticals